quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:52·162d
SECFiling
Avenue Therapeutics Inc. logo

Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

ATXI· Avenue Therapeutics Inc.
Health Care
Original source

Companies

  • ATXI
    Avenue Therapeutics Inc.
    Health Care

Related

  • SEC24d
    SEC Form 10-K filed by Avenue Therapeutics Inc.
  • SEC59d
    Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
  • PR59d
    Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
  • SEC107d
    Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.
  • INSIDER107d
    Large owner Fortress Biotech, Inc. was granted 111,209 shares, increasing direct ownership by 34% to 439,733 units (SEC Form 4)
  • SEC113d
    Avenue Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
  • SEC128d
    SEC Form EFFECT filed by Avenue Therapeutics Inc.
  • SEC129d
    SEC Form POS AM filed by Avenue Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022